Trastuzumab: A Picky Partner?MCARTHUR, Heather L; HUDIS, Clifford A.Clinical cancer research (Print). 2009, Vol 15, Num 20, pp 6311-6313, issn 1078-0432, 3 p.Article

Reversibility of Trastuzumab Cardiotoxicity : Is the Concept Alive and Well?EWER, Michael S; TAN-CHIU, Elizabeth; TELLI, Melinda L et al.Journal of clinical oncology. 2007, Vol 25, Num 34, pp 5532-5534, issn 0732-183X, 3 p.Article

From the trastuzumab era to new target therapies : beyond revolutionBARNI, S; PETRELLI, F; CABIDDU, M et al.Annals of oncology. 2007, Vol 18, issn 0923-7534, vi1-vi4, SUP6Conference Paper

Pertuzumab Protects the Achilles¹ Heel of Trastuzumab— EmtansineGWIN, William R; SPECTOR, Neil L.Clinical cancer research (Print). 2014, Vol 20, Num 2, pp 278-280, issn 1078-0432, 3 p.Article

Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise TrainingHAYKOWSKY, Mark J; MACKEY, John R; THOMPSON, Richard B et al.Clinical cancer research (Print). 2009, Vol 15, Num 15, pp 4963-4967, issn 1078-0432, 5 p.Article

Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?DEL MASTRO, L; BIGHIN, C; BINI, G et al.Annals of oncology. 2010, Vol 21, Num 6, pp 1376-1377, issn 0923-7534, 2 p.Article

Reproducibility of [¹¹C]Choline-Positron Emission Tomography and Effect of TrastuzumabKENNY, Laura M; CONTRACTOR, Kaiyumars B; HINZ, Rainer et al.Clinical cancer research (Print). 2010, Vol 16, Num 16, pp 4236-4245, issn 1078-0432, 10 p.Article

Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab TherapyGUANGLEI ZHUANG; BRANTLEY-SIEDERS, Dana M; VAUGHT, David et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 1, pp 299-308, issn 0008-5472, 10 p.Article

Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) TrialPROCTER, Marion; SUTER, Thomas M; COOMBES, R. Charles et al.Journal of clinical oncology. 2010, Vol 28, Num 21, pp 3422-3428, issn 0732-183X, 7 p.Article

Deconstructing media coverage of trastuzumab (Herceptin) : an analysis of national newspaper coverageWILSON, Paul M; BOOTH, Alison M; EASTWOOD, Alison et al.Journal of the Royal Society of Medicine. 2008, Vol 101, Num 3, pp 125-132, issn 0141-0768, 8 p.Article

Media influence on Herceptin subsidization in Australia : application of the rule of rescue?MACKENZIE, Ross; CHAPMAN, Simon; SALKELD, Glenn et al.Journal of the Royal Society of Medicine. 2008, Vol 101, Num 6, pp 305-312, issn 0141-0768, 8 p.Article

Trastuzumab-Induced HepatotoxicitySRINIVASAN, Sridhar; PARSA, Venkata; LIU, Chin Y et al.The Annals of pharmacotherapy. 2008, Vol 42, Num 10, pp 1497-1501, issn 1060-0280, 5 p.Article

Trastuzumab -associated peripheral vascular toxicityPANSEGRAU, Gary K; GRANT, Dennis R; NORRIS, Brian et al.Journal of clinical oncology. 2007, Vol 25, Num 11, pp 1438-1440, issn 0732-183X, 3 p.Article

High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)―mediated inhibition of platelet productionTHON, Jonathan N; DEVINE, Matthew T; JURAK BEGONJA, Antonija et al.Blood. 2012, Vol 120, Num 10, pp 1975-1984, issn 0006-4971, 10 p.Article

Concomitant trastuzumab with thoracic radiotherapy: a morphological and functional studyYAVAS, G; YILDIZ, F; GULER, S et al.Annals of oncology. 2011, Vol 22, Num 5, pp 1120-1126, issn 0923-7534, 7 p.Article

Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I EvaluationCARDINALE, Daniela; COLOMBO, Alessandro; NOLE, Franco et al.Journal of clinical oncology. 2010, Vol 28, Num 25, pp 3910-3916, issn 0732-183X, 7 p.Article

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancerBOYRAZ, Baris; SENDUR, Mehmet A. N; AKSOY, Sercan et al.Current medical research and opinion. 2013, Vol 29, Num 4, pp 405-414, issn 0300-7995, 10 p.Article

Nanomedicines for active targeting: Physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cellsCIRSTOIU-HAPCA, A; BUCHEGGER, F; BOSSY, L et al.European journal of pharmaceutical sciences. 2009, Vol 38, Num 3, pp 230-237, issn 0928-0987, 8 p.Article

Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCCBATTKE, Christina; RUISS, Romana; WELSCH, Ulrich et al.Cancer immunology and immunotherapy. 2011, Vol 60, Num 5, pp 639-648, issn 0340-7004, 10 p.Article

Detection of fluorine labeled Herceptin using cellular ¹⁹F MRI ex vivoBARTUSIK, Dorota; TOMANEK, Boguslaw.Journal of pharmaceutical and biomedical analysis. 2010, Vol 51, Num 4, pp 894-900, issn 0731-7085, 7 p.Article

Trastuzumab-Induced HER Reprogramming in Resistant Breast Carcinoma CellsNARAYAN, Murli; WILKEN, Jason A; HARRIS, Lyndsay N et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 6, pp 2191-2194, issn 0008-5472, 4 p.Article

Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival OutcomesMITTENDORF, Elizabeth A; YUN WU; HORTOBAGYI, Gabriel N et al.Clinical cancer research (Print). 2009, Vol 15, Num 23, pp 7381-7388, issn 1078-0432, 8 p.Article

SUCCESSFUL TREATMENT OF PULMONARY METASTATIC SALIVARY DUCTAL CARCINOMA WITH TRASTUZUMAB-BASED THERAPYPRAT, Aleix; PARERA, Marta; REYES, Vicky et al.Head & neck. 2008, Vol 30, Num 5, pp 680-683, issn 1043-3074, 4 p.Article

Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 AmplificationARNOULD, Laurent; ARVEUX, Patrick; FUMOLEAU, Pierre et al.Clinical cancer research. 2007, Vol 13, Num 21, pp 6404-6409, issn 1078-0432, 6 p.Article

Differential tumor cell targeting of anti-HER2 (Herceptin®) and anti-CD20 (Mabthera®) coupled nanoparticlesCIRSTOIU-HAPCA, A; BOSSY-NOBS, L; BUCHEGGER, F et al.International journal of pharmaceutics. 2007, Vol 331, Num 2, pp 190-196, issn 0378-5173, 7 p.Conference Paper